An overview of the evidence and the current recommendations in terms of MHT's role in preventing cardiovascular disease will be discussed as well as its safety in women with pre-existing cardiovascular disease.
In this Product Explainer, Dr. Robert Hungerford, GP with a special interest in ASCVD, heart failure and diabetes, explains the role of Semaglutide 2.4mg in weight management and cardiovascular risk reduction in secondary prevention.
Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA
Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.